SG11201809317VA - Methods for classifying patients with a solid cancer - Google Patents

Methods for classifying patients with a solid cancer

Info

Publication number
SG11201809317VA
SG11201809317VA SG11201809317VA SG11201809317VA SG11201809317VA SG 11201809317V A SG11201809317V A SG 11201809317VA SG 11201809317V A SG11201809317V A SG 11201809317VA SG 11201809317V A SG11201809317V A SG 11201809317VA SG 11201809317V A SG11201809317V A SG 11201809317VA
Authority
SG
Singapore
Prior art keywords
paris
international
solid cancer
medecine
inserm
Prior art date
Application number
SG11201809317VA
Inventor
Jérôme Galon
Bernhard Mlecnik
Franck Pages
Original Assignee
Inst Nat Sante Rech Med
Univ Sorbonne
Univ Paris Descartes
Univ Paris Diderot Paris 7
Hopitaux Paris Assist Publique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Sorbonne, Univ Paris Descartes, Univ Paris Diderot Paris 7, Hopitaux Paris Assist Publique filed Critical Inst Nat Sante Rech Med
Publication of SG11201809317VA publication Critical patent/SG11201809317VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6862—Ligase chain reaction [LCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111411 0 11101 HOE 010 1111 1 0 I OH 11101111110111011 11110 MAMIE Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/194556 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: (72) Inventors: GALON, Jerome; Inserm UMRS1138, Team GO1N 33/574 (2006.01) GOOF 19/00 (2011.01) 15, Cordeliers Research Center, 15 rue de Pecole de (21) International Application Number: medecine, 75006 PARIS (FR). MLECNIK, Bernhard; INSERM UMRS1138, Team 15, Cordeliers Research Cen- PCT/EP2017/061089 ter, 15 me de 1'Ecole de Medecine, 75006 Paris (FR). (22) International Filing Date: PAGES, Franck; INSERM UMRS1138,Team 15, Corde- 09 May 2017 (09.05.2017) hers Research Center, 15 Rue de 1'Ecole de Medecine, (25) Filing Language: English 75006 Paris (FR). (26) Publication Language: English (74) Agent: CABINET PLASSERAUD; 66 me de la Chaussee d'Antin, 75440 PARIS CEDEX 09 (FR). (30) Priority Data: (81) Designated States (unless otherwise indicated, for every 16305536.1 09 May 2016 (09.05.2016) EP kind of national protection available): AE, AG, AL, AM, (71) Applicants: INSERM (INSTITUT NATIONAL DE AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, LA SANTE ET DE LA RECHERCHE MEDICALE) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, [FR/FR]; 101, me de Tolbiac, 75013 PARIS (FR). DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, UNIVERSITE PIERRE ET MARIE CURIE (PARIS HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, 6) [FR/FR]; 4, Place Jussieu, 75005 PARIS (FR). KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, UNIVERSITE PARIS DESCARTES [FR/FR]; 12, me de MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, l'Ecole de Medecine, 75006 PARIS 6 (FR). UNIVERSITE PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, PARIS DIDEROT - PARIS 7 [FR/FR]; 5, me Thomas SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, Mann, 75013 PARIS (FR). ASSISTANCE PUBLIQUE TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = - HOPITAUX DE PARIS [FR/FR]; 3 Avenue Victoria, (84) Designated States (unless otherwise indicated, for every 75004 Paris (FR). kind of regional protection available): ARIPO (BW, GH, — GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = (54) Title: METHODS FOR CLASSIFYING PATIENTS WITH A SOLID CANCER (57) : The invention relates to methods for clas- present = 51 _ SELECTION sifying patients suffering from a solid cancer, particularly to meth- i f ods for the prognosis of the survival time of a patient suffering = S 2 PREPARATION from a solid cancer and/or to methods for assessing the respon- siveness of a patient suffering from a solid cancer to antitumoral — treatment. The method is based on multiple immune quantifying 53 KIT =response markers and determining to which percentile of the dis- = tribution the values correspond when compared to a reference dis- - n=n+1 — 54 tribution. Calculating the mean or median of the determined per- = ASSAY the different this to = , centiles of markers and comparing value a reference value of the mean- or median percentiles, the result of = 55 MEASURE n=n+1 4.-. , .---- which is correlated with survival or responsiveness = • I , 56 QC slt _ 57 DATA 1-1 Ss ALGORITHM SID A 511 ii . in 59 SCORE:.:MODEL DECISION 1-1 Ir -- -- 11 FIGURE 2 © ei C [Continued on next page] WO 2017/194556 Al MIDEDIMOMOIDEIROIDEMOMOHMOHIMHOMEMOIMIE UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
SG11201809317VA 2016-05-09 2017-05-09 Methods for classifying patients with a solid cancer SG11201809317VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305536 2016-05-09
PCT/EP2017/061089 WO2017194556A1 (en) 2016-05-09 2017-05-09 Methods for classifying patients with a solid cancer

Publications (1)

Publication Number Publication Date
SG11201809317VA true SG11201809317VA (en) 2018-11-29

Family

ID=56014938

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809317VA SG11201809317VA (en) 2016-05-09 2017-05-09 Methods for classifying patients with a solid cancer

Country Status (13)

Country Link
US (1) US20190309369A1 (en)
EP (1) EP3455631B1 (en)
JP (3) JP7281903B2 (en)
KR (1) KR102245021B1 (en)
CN (2) CN109690314B (en)
AU (1) AU2017261685B2 (en)
ES (1) ES2808004T3 (en)
MX (1) MX2018013744A (en)
PL (1) PL3455631T3 (en)
RU (1) RU2745730C2 (en)
SG (1) SG11201809317VA (en)
WO (1) WO2017194556A1 (en)
ZA (1) ZA201807020B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3639170B1 (en) 2017-06-13 2021-03-24 BostonGene Corporation Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
WO2019020556A1 (en) 2017-07-24 2019-01-31 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
WO2019149817A1 (en) * 2018-01-31 2019-08-08 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iii colorectal cancer
FR3079617B1 (en) * 2018-03-29 2023-12-22 Office National Detude Et De Rech Aerospatiales Onera METHOD FOR DETECTING CELLS PRESENTING AT LEAST ONE ANOMALY IN A CYTOLOGICAL SAMPLE
BR112021024374A8 (en) * 2019-06-03 2022-12-06 Inst Nat Sante Rech Med METHOD TO MODULATE A TREATMENT REGIME
CN110988324B (en) * 2019-11-29 2021-08-24 广州市雷德医学检验实验室有限公司 Immune state determination system, method, device and storage medium
CN111257563B (en) * 2020-01-22 2022-08-23 广州泛恩生物科技有限公司 Application of CXCL13 detection agent in preparation of kit for predicting immunotherapy effect
CN111999503B (en) * 2020-05-28 2022-05-20 首都医科大学附属北京地坛医院 Marker for predicting acute viral respiratory infectious disease severity and application and kit thereof
CN113174439B (en) * 2021-03-30 2022-06-28 中国医学科学院肿瘤医院 Application of immune gene pair scoring system in predicting immunotherapy effect of non-small cell lung cancer patient
EP4330676A1 (en) * 2021-04-27 2024-03-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for predicting the risk of lymph node metastasis and/or recurrence of patients suffering from a t1 cancer treated by endoscopic resection
KR20220155554A (en) * 2021-05-13 2022-11-23 주식회사 센트릭스바이오 Combination treatment with anti cd300c antibody
WO2023175366A1 (en) 2022-03-17 2023-09-21 Veracyte Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
WO2023233310A1 (en) * 2022-06-03 2023-12-07 Universita' Degli Studi Di Roma "La Sapienza" Method for determining the prognostic score in patients with metastatic renal carcinoma
CN115747331B (en) * 2022-09-22 2023-08-25 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Three-level lymphoid structure component marker combination, system and application for predicting nasopharyngeal carcinoma prognosis
TWI826081B (en) * 2022-10-28 2023-12-11 臺北醫學大學 Cancer progression assessment method and system thereof
CN117476097B (en) * 2023-10-25 2024-06-07 中山大学附属第六医院 Colorectal cancer prognosis and treatment response prediction model based on tertiary lymphoid structure characteristic genes, and construction method and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053272A1 (en) * 2005-05-11 2007-04-25 Hoffmann La Roche DETERMINATION OF RESPONSIVES TO CHEMOTHERAPY
NZ595471A (en) * 2009-04-14 2014-01-31 Nestec Sa Inflammatory bowel disease prognostics
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
WO2013107900A1 (en) * 2012-01-20 2013-07-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of a patient suffering from a solid cancer based on density of b cells
KR102179848B1 (en) * 2012-06-14 2020-11-17 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Method for quantifying immune cells in tumoral tissues and its applications
JP6923291B2 (en) * 2012-07-12 2021-08-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル A method for predicting survival and treatment responsiveness of patients with solid tumors using the signatures of at least 7 genes
CA2881389C (en) 2012-08-06 2022-01-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and kits for screening patients with a cancer
JP2016530505A (en) * 2013-07-15 2016-09-29 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル A method for determining the prognosis of survival in patients with solid cancer

Also Published As

Publication number Publication date
PL3455631T3 (en) 2021-04-06
AU2017261685A1 (en) 2018-11-15
JP7281903B2 (en) 2023-05-26
KR102245021B1 (en) 2021-04-26
MX2018013744A (en) 2019-08-16
RU2745730C2 (en) 2021-03-31
EP3455631A1 (en) 2019-03-20
AU2017261685B2 (en) 2023-09-07
CN109690314A (en) 2019-04-26
JP2024019551A (en) 2024-02-09
RU2018143409A (en) 2020-06-10
WO2017194556A1 (en) 2017-11-16
BR112018072993A2 (en) 2019-03-06
JP2019516979A (en) 2019-06-20
JP2022027788A (en) 2022-02-14
EP3455631B1 (en) 2020-06-24
BR112018072993A8 (en) 2022-11-08
US20190309369A1 (en) 2019-10-10
CN109690314B (en) 2022-08-02
KR20190016025A (en) 2019-02-15
ZA201807020B (en) 2020-05-27
CN115198018A (en) 2022-10-18
ES2808004T3 (en) 2021-02-25
RU2018143409A3 (en) 2020-06-29

Similar Documents

Publication Publication Date Title
SG11201809317VA (en) Methods for classifying patients with a solid cancer
SG11201809294RA (en) Systems and methods for sensor data analysis through machine learning
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201808820QA (en) Methods and kits for the diagnosis and risk stratification of patients with ischemia
SG11201908564RA (en) Devices, processes, and systems for determination of nucleic acid sequence, expression, copy number, or methylation changes using combined nuclease, ligase, polymerase, and sequencing reactions
SG11201805835WA (en) Modified oncolytic virus
SG11201804723WA (en) Drowsiness onset detection
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201809606YA (en) Combination therapy for cancer treatment
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201901621VA (en) Development of spinal cord on a microfluidic chip
SG11201408107RA (en) Method for quantifying immune cells in tumoral tissues and its applications
SG11201807972YA (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201807501UA (en) Method and system for imaging
SG11201810694WA (en) Use of biomarkers in determining susceptibility to disease treatment
SG11201810544WA (en) Detecting hematological disorders using cell-free dna in blood
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201900253TA (en) Method and system for microbial pharmacogenomics
SG11201808830YA (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201909501TA (en) Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro
SG11201811125XA (en) Image-based diagnostic systems
SG11201805755SA (en) Methods of administering hepcidin